CRANFORD, NJ, USA I January 7, 2025 I Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, ...

NEW YORK, NY, USA I January 07, 2025 I Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...

SEATTLE, WA, USA I January 7, 2025 I Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo ...

Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 ...

BEIJING, China & ALAMEDA, CA, China & TAIPEI, Taiwan I January 07, 2025 I Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a ...

The Company has aligned on clinical plan based on a positive FDA meeting, leveraging clinical data from a first-in-human Phase 1 trial published today in ...

New investor Jeito Capital, a global leading private equity fund, led the Series B financing round which also included existing institutional investors EQT, Fountain Healthcare Partners, and Lumira ...

ROCKVILLE, MD, USA I January 6, 2025 I I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...

Under the terms of the agreement, the licensee will obtain rights to develop, secure regulatory approval for, and commercialize SPD8 in the designated market. The licensing agreement includes ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications ...

SOUTH SAN FRANCISCO, CA, USA I January 06, 2025 I Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the ...

SAN DIEGO, CA, USA & SHANGHAI, China I January 06, 2024 I Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming ...